These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 30539506)

  • 1. Immunotherapy in Lung Cancer: A New Age in Cancer Treatment.
    Corrales L; Scilla K; Caglevic C; Miller K; Oliveira J; Rolfo C
    Adv Exp Med Biol; 2018; 995():65-95. PubMed ID: 30539506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapy in the Treatment of Lung Cancer].
    Fiala O; Šorejs O; Pešek M; Fínek J
    Klin Onkol; 2017; 30(Supplementum3):22-31. PubMed ID: 29239189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
    Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma].
    Berghmans T; Grigoriu B; Sculier JP; Meert AP
    Rev Mal Respir; 2018 Feb; 35(2):197-205. PubMed ID: 29395567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel immunotherapy in the treatment of advanced non-small cell lung cancer.
    Santabarbara G; Maione P; Rossi A; Palazzolo G; Gridelli C
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1571-1581. PubMed ID: 27623999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Mignard X; Chaabane N; Fallet V; Wislez M
    Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.
    Proto C; Ferrara R; Signorelli D; Lo Russo G; Galli G; Imbimbo M; Prelaj A; Zilembo N; Ganzinelli M; Pallavicini LM; De Simone I; Colombo MP; Sica A; Torri V; Garassino MC
    Cancer Treat Rev; 2019 May; 75():39-51. PubMed ID: 30954906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?
    Ramamurthy C; Godwin JL; Borghaei H
    Curr Treat Options Oncol; 2017 Jun; 18(6):33. PubMed ID: 28534248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunotherapy for lung cancer].
    Ostoros G
    Magy Onkol; 2017 Jun; 61(2):153-157. PubMed ID: 28585617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
    Kumar R; Collins D; Dolly S; McDonald F; O'Brien MER; Yap TA
    Curr Probl Cancer; 2017; 41(2):111-124. PubMed ID: 28214087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis.
    El-Osta H; Jafri S
    Immunotherapy; 2019 Feb; 11(3):189-199. PubMed ID: 30730276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.